Every January, the biotech world connects in San Francisco for the J.P. Morgan Healthcare Conference, a gathering where innovation meets investment, and everyone is talking about what's next in our industry. For RareMoon, JPM is the place where we kick off our year in conversations with individuals who have a similar drive for accelerating rare disease therapies. In fact, every one of our ten years in business has been kicked off at JPM, making this year particularly meaningful as we enter our decade milestone!
So why does RareMoon attend JPM, and why does it consistently stand out as our most successful and high-impact conference of the year? For us, it's a combination of industry insight, strategic conversations, relationship-building, and forward-looking regulatory planning, all in one very concentrated week.
Our meetings are hosted by our founding members; Co-Founder & CEO, Sabrina Mogle is joined by Co-Founder and COO, Chris Novashinski, and founding member and regulatory expert, Fred Loussala. This year, Sarah DiSalvatore, RareMoon's Clinical Operations Leadership Consultant, will also be joining. And, for some meetings, we'll be accompanied by a strategic partner and lead statistician, Robert Rachford.
Meeting Clients, Prospective Clients, and Industry Partners
With 40–50 meetings each year, JPM allows us to do what we do best: connect intentionally with the biotech community. A big part of our week is spent sitting down with our current clients, aligning on their 2026 regulatory milestones, agency interactions, and designation strategies, and helping them prepare for pivotal conversations.
Just as important, JPM provides us the opportunity to meet prospective clients and emerging biotech leaders who are looking for expertise in an increasingly complex regulatory landscape. These conversations often revolve around readying a program for investor/regulatory feedback, and from there, follow-up calls are conducted, where the roadmap begins to take shape.
JPM also brings together investors, BD teams, and potential partners, and RareMoon frequently supports our clients in these meetings. Whether helping articulate regulatory strategy to investors or highlighting key milestones, we serve as a strategic ally during one of the most negotiation-heavy weeks on the biotech calendar.
Announcing New Team Members and Strategic Partnerships
This year, 2026, marks an especially exciting year for RareMoon. As we enter our 10th year, we are announcing several new team members, a new service portfolio aimed at streamlining communication between regulatory milestones and clinical start-up activities, and strategic partnerships designed to expand our service offerings and enhance the support we provide to clients developing orphan drugs and advanced therapies.
JPM is the ideal platform for these announcements as the conversations we have throughout the week naturally highlight how these partnerships will benefit sponsors and accelerate development programs.
What We Do at JPM, And Why It Works
RareMoon arrives at JPM with structure and intention. Our team:
- Conducts 40–50 strategic meetings across the week
- Aligns current clients with 2026 regulatory priorities
- Meets new prospective clients seeking regulatory partnership
- Supports investor and BD conversations
- Shares regulatory insights and upcoming expectations
Looking Ahead to an Exciting Year
As we step into 2026, we do so with the same energy and commitment that has defined RareMoon since day one. Starting the year off meeting clients and prospective clients with that same drive and commitment to the rare disease community, for us, is a perfect way to start the year.
Here's to the conversations, collaborations, and breakthroughs that begin at JPM, and to an exciting 10th year for RareMoon Consulting!